It is important to note that: Most clinical trials have follow-up periods of 25 years, which may not capture very long-term cancer development Patients with type 2 diabetes and obesity have baseline elevated cancer risks due to metabolic factors Post-marketing surveillance continues to monitor for rare or delayed adverse events The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) continue to review safety data as part of ongoing pharmacovigilance activities, and no major cancer-related safety signals have emerged that would warrant withdrawal or significant restriction of these medicines
Collective data from major clinical trials have shown that treatment with a DPP-4i improves glycemic control by increasing insulin secretion from islet cells, lowering levels of HbA1c, reducing adipocyte size, and suppressing inflammation [47,48,49,50,51]
For pharma marketers, the FDAs action carries implications beyond the compounding sector itself
[5] Contact HR or your benefits administrator to ask about exceptions
There are other products worth checking also but the ones shown are my personal favourite